Plaque Stabilization News Today : Breaking News, Live Update

Elixir Medical To Present Randomized Clinical Dataset Featuring World's First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

Published: October 10, 2023

Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk

Source: dicardiology.com

Elixir Medical Corporation: EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical's DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

Published: May 17, 2023

First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving significantly

Source: finanznachrichten.de

Early PCSK9 Inhibition in AMI Yields Plaque Regression

Published: April 5, 2022

"Go early and go low" is an expert's response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.

Source: medscape.com

Plaque Stabilization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Plaque Stabilization Today - Breaking & Trending Today

Elixir Medical To Present Randomized Clinical Dataset Featuring World's First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

Elixir Medical Corporation: EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical's DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

Early PCSK9 Inhibition in AMI Yields Plaque Regression